• FDA Provides Emergency Use Authorisation for Serological Test to Identify COVID-19 Antibodies

Laboratory Products

FDA Provides Emergency Use Authorisation for Serological Test to Identify COVID-19 Antibodies

May 11 2020

PerlinElmer Inc has announced that the US Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for Euroimmun’s (a PerkinElmer company) Anti-SARS-CoV-2 ELISA (IgG) serology test. Clinical laboratories certified to perform high complexity tests under Clinical Laboratory Improvement Amendments (CLIA) can immediately begin using this ELISA for the detection of antibodies of the immunoglobulin class G.

 

Serological tests detect antibodies in the blood and are detected when an immune reaction to the pathogen has already taken place. These tests can determine who had previously been infected with COVID-19 (2-4 weeks or more prior to testing) and may have developed immunity. How long antibodies last and whether they are protective is being actively studied. The Euroimmun Anti-SARS-CoV-2 ELISA (IgG) is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. The Euroimmun Anti-SARS-CoV-2 ELISA (IgG) has 99% specificity and 100% sensitivity after 21 days following the onset of symptoms.

 

“Leading with science is a fundamental part of our DNA at PerkinElmer, and the Euroimmun team recognised early on that understanding the pathogenesis of COVID-19 from a cellular biology level is paramount to developing a highly accurate and reliable antibody test,” said Prahlad Singh, President and Chief Executive officer, PerkinElmer. “As a result, the antigen used in the Euroimmun Anti-SARS-CoV-2 ELISA (IgG), the spike protein S1 domain, is more likely to reflect virus neutralising antibodies than antibodies to N capsid nucleoprotein. This is also supported by the fact that most of the COVID-19 vaccine development programs in the US and worldwide have chosen the spike protein as their target.”

 

“It is possible that 50% or more of people who have been infected with COVID-19 might not display symptoms, making it difficult to identify those who have previously contracted COVID-19,” said Prahlad Singh. “That’s why serological testing that utilises an antigen highly specific to SARS-CoV-2 is such an important tool in understanding how pervasive this virus is.”

 

Euroimmun has the capacity to manufacture millions of assays per month. Since March, it has already started shipping its Anti-SARS-CoV-2 ELISA (IgG) to leading laboratories across the globe. Euroimmun intends to further build production capacity to meet heightened demand. 

 

More information online


Digital Edition

International Labmate July 2021

July 2021

In This Edition Articles - Deep characterisation and quantitative analysis - Seamless HPLC Method Transfer - How does a sample’s adventure unfold at Diamond? Mass Spectrometry & Spectr...

View all digital editions

Events

InformEx Zone at CPhl North America

Aug 10 2021 Pennsylvania, PA, USA & Online

Miconex

Aug 18 2021 Beijing, China

DioXin 2021

Aug 22 2021 Xi'an, China

ACS National Meeting & Expo, Fall 2021

Aug 22 2021 Atlanta, GA, USA & Virtual

Microscopy Conference 2021

Aug 22 2021 Digital event

View all events